FRANKFURT (dpa-AFX) - Sartorius shares continued their recovery from the low for the year on Thursday. At 228.60 euros, the shares of the laboratory equipment manufacturer were up almost 15 percent on Tuesday, when they had reached their lowest level since March 2020 at just under 200 euros. Even now, they are still the weakest DAX stock of 2024 with a one-third annual loss. However, analyst Oliver Metzger from Oddo BHF is optimistic that this will change and recommended the shares with a price target of EUR 260.

The expert assumes that Gottingen will grow faster than the biopharma market. In addition, the burdensome reduction in customer inventories should soon come to an end. However, order behavior has changed - orders are smaller, but more frequent. Incoming orders could therefore continue to weaken visually in comparison until the new behavior is reflected in the figures. According to Metzger, sales growth should pick up more quickly.

The shares of the subsidiary Sartorius Stedim Biotech showed a similar picture on Euronext. Metzger also issued a recommendation here./ag/mis